Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea
International Journal of Hematology, 05/24/2012
Kim D et al. – Treatment adherence in the early treatment period was one of the important independent predictors of favorable long–term outcome. Durable cytogenetic and molecular responses were maintained in a majority of patients treated with optimal dose intensity.